Gender, n (%)
|
Male
|
45 (49)
|
Female
|
44 (51)
|
Age, n (%)
|
< 60 years
|
57 (64)
|
≥ 60 years
|
32 (36)
|
Race, n (%)
|
Non-Hispanic White
|
63 (71)
|
African-American
|
18 (20)
|
Hispanic
|
8 (9)
|
Performance status, n (%)
|
0
|
35 (39)
|
1
|
49 (55)
|
2
|
5 (6)
|
Histological grade
|
Well
|
3 (3)
|
Moderate
|
69 (78)
|
Poor
|
17 (19)
|
Number of metastatic sites
|
< 3
|
42 (47)
|
≥ 3
|
47 (53)
|
Serum albumin
|
Normal
|
72 (81)
|
Low (<3.5 g/dL)
|
17 (19)
|
Serum LDH
|
Normal
|
19 (21)
|
Elevated (>618 IU/L)
|
70 (79)
|
RMH Score
|
< 2
|
43 (48)
|
≥ 2
|
46 (52)
|
KRAS exon 2 wild-typea
|
89 (100)
|
KRAS non-exon 2 mutations (n = 70)
|
0
|
NRAS mutations (n = 23)
|
0
|
BRAF V600E mutation (n = 64)
|
0
|
PIK3CA mutations (n = 37)
|
6
|